Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $3.11, $0.83 better than the analyst estimate of $2.28. Revenue for the quarter came in at $1.79 billion versus the consensus estimate of $1.72 billion.

GUIDANCE:

Vertex Pharma sees FY2021 revenue of $7.2-7.4 billion, versus the consensus of $6.99 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.